Abortion in Australia – access and legal issues

Abortion in Australia – access and legal issues

2014-12-01 00:00:00

In 2010-11, 49% of Children by Choice’s client contacts identified the cost of abortion as a barrier to access. In addition 21% identified geography as a problem. In 2011-12, the average travel distance for our RRR clients who received financial assistance to access abortion was 857km each way. Many health professionals and women’s health advocates hope that the TGA approval of mifepristone in 2012 for use in Australia for early medical abortion will improve access to services for Queensland women. Internationally, mifepristone has been used safely and effectively for early medical abortion up to 63 days LMP for over two decades. Best practice guidelines and international evidence show that local provision of early medical abortion is preferable rather than women having to travel large distances to access a service. Australian general practitioners who complete free online training will be able to prescribe the drug. This offers the opportunity for the provision of early medical abortion by local GPs to their patients outside of the current day hospital settings.

However, there are a number of issues such as government cost subsidisation of the drug to make it more affordable, gestational limitations, professional indemnity insurance, navigating Queensland abortion law and the development of local referral and support pathways, which need to be addressed before the availability of mifepristone can improve RRR Queensland women’s access to abortion. This presentation will also discuss some of these concerns and explore solutions.

Speakers: Cait Calcutt
Conference: ASHM 2013
Areas of Interest / Categories: Australian Society for HIV 2013
Play
My List

Australian Society for HIV 2013

Delayed HIV diagnoses among gay and bisexual men in Australia

Delayed HIV diagnoses among gay and bisexual men in Australia

The majority of HIV diagnoses including delayed diagnoses in Australia occur among men who report homosexual contact – hereafter called gay and bisexual men (GBM). Delayed diagnosis is strongly associated with increased HIV-related mortality and morbidity. People who are unaware of their HIV-positive status may also be unwittingly transmitting HIV. We assessed trends in delayed HIV diagnoses among GBM in Australia.

Complex case report that illustrates the paucity of data for long term management of Visceral Leishmania-HIV co-infection.

Complex case report that illustrates the paucity of data for long term management of Visceral Leishmania-HIV co-infection.

HIV-associated leishmaniasis, endemic in the Mediterranean basin is a growing problem in India, Brazil and East Africa. Despite surviving for than 20 years, the clinical course of our visceral-leishmania (VL)-HIV co-infected patient illustrates several management challenges including diagnosis, speciation and drug resistance; monitoring burden of disease; access to and use of VL-treatments; end-organ toxicity and the combined immunosuppressive effects of HIV-VL.

Clinical factors associated with suboptimal adherence to antiretroviral therapy in Asia

Clinical factors associated with suboptimal adherence to antiretroviral therapy in Asia

Adherence to combination antiretroviral therapy (cART ) plays an important role on treatment outcomes. The TREAT Asia Studies to Evaluate Resistance – Monitoring Cohort Study (TASER-M) collects patients’ adherence based on a Visual Analogue Scale. The aim of this analysis was to assess the rates of, and factors associated with, suboptimal adherence in the first 24 months of initial cART in Asian patients.

Reinvigorating evidence for action and capacity in community HIV programs (REACH Project)

Reinvigorating evidence for action and capacity in community HIV programs (REACH Project)

REACH was a collaborative research and practice initiative to develop evidence building frameworks, capacity, tools and resources with the Victorian HIV community partnership.

The impact of immune activation on natural killer cells in the setting of HIV infection

The impact of immune activation on natural killer cells in the setting of HIV infection

HIV disease is associated with chronic inflammation and activation of the innate immune system. This state, as measured using plasma markers of inflammation, persists following suppression of HIV viremia using antiretroviral therapy, and may increase risk of non-AIDS co-morbidities. The causes of innate immune activation in the setting of virological suppression are unclear. Natural killer (NK) cells are innate immune cells that kill virus-infected and transformed cells without prior sensitization. We have shown that NK cells are activated both phenotypically (elevated expression of HLA-DR) and functionally (increased spontaneous degranulation measured by CD107a surface expression) in virologically suppressed (VS) HIV+ individuals. NK cells also lose expression of CD16, the receptor which mediates antibody-dependent cellular cytotoxicity.

Men who take more risks avoid HIV testing due to structural barriers

Men who take more risks avoid HIV testing due to structural barriers

Regular HIV testing is recommended in men who take sexual risks. We assessed the relationship between perceived barriers to HIV testing, and frequency of testing among men who engaged in unprotected anal intercourse with casual partners (UAIC), to inform HIV testing strategies.

Behavioural trends among Australian gay men pose increasing challenges for HIV prevention: findings from the Gay Community Periodic Surveys, 2003-1

Behavioural trends among Australian gay men pose increasing challenges for HIV prevention: findings from the Gay Community Periodic Surveys, 2003-1

Gay men remain the primary population affected by HIV in Australia. While recent attention has been focused on increasing HIV testing and the use of antiretroviral-based prevention to reduce infections, it is equally important to sustain safe sex and other risk reduction practices. Increases in unprotected anal intercourse (UAI), for example, may counteract any beneficial changes in testing and treatment.